Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Other EventsItem 8.01 Other Events.
On April16, 2018, Eagle Pharmaceuticals,Inc., or the Company, issued a press release announcing that the Company has submitted and the U.S. Food and Drug Administration has accepted for filing its abbreviated new drug application (ANDA) for vasopressin injection, 1ml.
A copy of the press release referenced above is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
Press Release dated April16, 2018
EAGLE PHARMACEUTICALS, INC. ExhibitEX-99.1 2 a18-10132_1ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release Eagle Pharmaceuticals Vasopressin ANDA Accepted for Filing by the FDA WOODCLIFF LAKE,…To view the full exhibit click here About Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty. Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Recent Trading Information Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) closed its last trading session up +1.46 at 53.87 with shares trading hands.